Fecal Occult Blood Testing When Colonoscopy Capacity is Limited

被引:57
|
作者
Wilschut, Janneke A. [1 ]
Habbema, J. Dik F. [1 ]
van Leerdam, Monique E. [2 ]
Hol, Lieke [2 ]
Lansdorp-Vogelaar, Iris [1 ]
Kuipers, Ernst J. [2 ,3 ]
van Ballegooijen, Marjolein [1 ]
机构
[1] Univ Med Ctr Rotterdam, Erasmus MC, Dept Publ Hlth, NL-3000 CA Rotterdam, Netherlands
[2] Univ Med Ctr Rotterdam, Erasmus MC, Dept Gastroenterol & Hepatol, NL-3000 CA Rotterdam, Netherlands
[3] Univ Med Ctr Rotterdam, Erasmus MC, Dept Internal Med, NL-3000 CA Rotterdam, Netherlands
来源
关键词
COLORECTAL-CANCER MORTALITY; SCREENING-PROGRAM; IMPACT; COSTS; PROJECTIONS; STATES; POLYP; LIFE; CARE;
D O I
10.1093/jnci/djr385
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Fecal occult blood testing (FOBT) can be adapted to a limited colonoscopy capacity by narrowing the age range or extending the screening interval, by using a more specific test or hemoglobin cutoff level for referral to colonoscopy, and by restricting surveillance colonoscopy. Which of these options is most clinically effective and cost-effective has yet to be established. We used the validated MISCAN-Colon microsimulation model to estimate the number of colonoscopies, costs, and health effects of different screening strategies using guaiac FOBT or fecal immunochemical test (FIT) at various hemoglobin cutoff levels between 50 and 200 ng hemoglobin per mL, different surveillance strategies, and various age ranges. We optimized the allocation of a limited number of colonoscopies on the basis of incremental cost-effectiveness. When colonoscopy capacity was unlimited, the optimal screening strategy was to administer an annual FIT with a 50 ng/mL hemoglobin cutoff level in individuals aged 45-80 years and to offer colonoscopy surveillance to all individuals with adenomas. When colonoscopy capacity was decreasing, the optimal screening adaptation was to first increase the FIT hemoglobin cutoff value to 200 ng hemoglobin per mL and narrow the age range to 50-75 years, to restrict colonoscopy surveillance, and finally to further decrease the number of screening rounds. FIT screening was always more cost-effective compared with guaiac FOBT. Doubling colonoscopy capacity increased the benefits of FIT screening up to 100%. FIT should be used at higher hemoglobin cutoff levels when colonoscopy capacity is limited compared with unlimited and is more effective in terms of health outcomes and cost compared with guaiac FOBT at all colonoscopy capacity levels. Increasing the colonoscopy capacity substantially increases the health benefits of FIT screening.
引用
收藏
页码:1741 / 1751
页数:11
相关论文
共 50 条
  • [1] Prevalence and predictors of fecal occult blood testing after colonoscopy
    Fisher, Deborah A.
    Grubber, Janet
    Coffman, Cynthia J.
    Voils, Corrine I.
    Vernon, Sally W.
    Provenzale, Dawn
    GASTROENTEROLOGY, 2008, 134 (04) : A160 - A160
  • [2] Preference for Colonoscopy in a Program of Annual Fecal Occult Blood Testing
    Zauber, Ann
    Winawer, Sidney
    Church, Timothy
    Allen, John
    Mandelson, Margaret
    Feld, Andrew
    Mills, Glenn
    Jordan, Paul
    Ruckel, Julie
    O'Brien, Michael
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 : S566 - S567
  • [3] The usage and significance of fecal occult blood testing after normal colonoscopy
    Womeldorph, CM
    Mulhall, BP
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (10): : S324 - S324
  • [4] Preprocedure Haemoglobin and Fecal Occult Blood Testing for Optimising Colonoscopy Rates in a Resource Limited Setting for Diagnosing Colonic Malignancy
    Dutta, Amit K.
    Pl, Alagammai
    Chowdhury, Sudipta D.
    Chacko, Ashok
    GASTROINTESTINAL ENDOSCOPY, 2012, 75 (04) : 325 - 326
  • [5] The frequency of fecal occult blood testing after colonoscopy in patients with adenomatous polyps
    Weiner, JJ
    Happe, MR
    Maydonovitch, CL
    Mulhall, BP
    GASTROENTEROLOGY, 2004, 126 (04) : A57 - A57
  • [6] Interval fecal occult blood testing in a colonoscopy based screening program.
    Cole, SR
    Sandford, JJ
    Cadd, BA
    Bennett, J
    Young, GP
    Bampton, PA
    GASTROENTEROLOGY, 2001, 120 (05) : A603 - A603
  • [7] FECAL OCCULT BLOOD TESTING
    FROMMER, D
    KAPPARIS, A
    LANCET, 1983, 2 (8352): : 738 - 738
  • [8] Fecal Occult Blood Testing
    Sanford, Kimberly W.
    McPherson, Richard A.
    CLINICS IN LABORATORY MEDICINE, 2009, 29 (03) : 523 - +
  • [9] Fecal occult blood testing
    Anderson, J
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 1996, 91 (08): : 1671 - 1671
  • [10] FECAL OCCULT BLOOD TESTING
    WINAWER, SJ
    AMERICAN JOURNAL OF DIGESTIVE DISEASES, 1976, 21 (10): : 885 - 888